Literature DB >> 11605097

Effect of gabapentin-like compounds on development and maintenance of morphine-induced conditioned place preference.

N Andrews1, S Loomis, R Blake, L Ferrigan, L Singh, A T McKnight.   

Abstract

RATIONALE: Psychological dependence to the opioid analgesic morphine is attributable to the rewarding properties of the drug, and its evolution can be divided into two distinct phases: development and maintenance. Both phases can be studied using conditioned place preference (CPP).
OBJECTIVES: To determine whether the two phases can be influenced by pre-treatment with gabapentin-like compounds.
METHODS: CPP to morphine was used to demonstrate the rewarding properties of morphine in the presence or absence of gabapentin-like compounds. In-vivo microdialysis in the nucleus accumbens was used to determine the effects of gabapentin or pregabalin on morphine-induced dopamine release.
RESULTS: Pretreatment with either gabapentin (10-100 mg/kg p.o.) or pregabalin (3-30 mg/kg p.o.) attenuated CPP induced by a submaximal dose of morphine (0.75 mg/kg). Neither gabapentin nor pregabalin had any effect alone in the CPP test. Both gabapentin-like compounds blocked the effect of morphine (0.75 mg/kg s.c.) to increase the release of dopamine in the nucleus accumbens. Studies of the maintenance of CPP to morphine showed CPP was maintained for at least 4 days after the initial test. In a second experiment, it was found that pregabalin (injected once, 24 h after CPP had been demonstrated) was able to reverse morphine-induced CPP.
CONCLUSIONS: Neither gabapentin nor pregabalin induced CPP, but both compounds blocked the development of CPP to morphine and also blocked morphine's effects on dopamine release. Furthermore, pregabalin blocked the maintenance of morphine-induced CPP. It is concluded that gabapentin-like compounds, which have no intrinsic rewarding properties, may have some therapeutic use in the treatment of opioid dependence.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11605097     DOI: 10.1007/s002130100839

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  15 in total

1.  Pregabalin- and topiramate-mediated regulation of cognitive and motor impulsivity in DBA/2 mice.

Authors:  Francisco Navarrete; José M Pérez-Ortiz; Jorge Manzanares
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

Review 2.  Abuse Potential of Pregabalin: A Systematic Review.

Authors:  Ole Schjerning; Mary Rosenzweig; Anton Pottegård; Per Damkier; Jimmi Nielsen
Journal:  CNS Drugs       Date:  2016-01       Impact factor: 5.749

3.  Gabapentin completely attenuated the acute morphine-induced c-Fos expression in the rat nucleus accumbens.

Authors:  Jamil Ahsan Kazi; Mohamed Ibrahim Abu-Hassan
Journal:  J Mol Neurosci       Date:  2010-08-24       Impact factor: 3.444

4.  Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure.

Authors:  Nichole C Sanders; Michael J Mancino; W Brooks Gentry; J Benjamin Guise; Warren K Bickel; Jeff Thostenson; Alison H Oliveto
Journal:  Exp Clin Psychopharmacol       Date:  2013-07-15       Impact factor: 3.157

5.  Consuming illicit opioids during a drug overdose epidemic: Illicit fentanyls, drug discernment, and the radical transformation of the illicit opioid market.

Authors:  Sarah E Duhart Clarke; Alex H Kral; Jon E Zibbell
Journal:  Int J Drug Policy       Date:  2021-10-15

6.  Gabapentin completely attenuated the acute morphine induced c-Fos expression in the rat striatum.

Authors:  Jamil Ahsan Kazi; Chen Fun Gee
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 3.444

7.  Discriminative stimulus effects of tiagabine and related GABAergic drugs in rats.

Authors:  L M McDonald; W F Sheppard; S M Staveley; B Sohal; F D Tattersall; P H Hutson
Journal:  Psychopharmacology (Berl)       Date:  2008-02-09       Impact factor: 4.530

Review 8.  Tolerance and withdrawal from prolonged opioid use in critically ill children.

Authors:  Kanwaljeet J S Anand; Douglas F Willson; John Berger; Rick Harrison; Kathleen L Meert; Jerry Zimmerman; Joseph Carcillo; Christopher J L Newth; Parthak Prodhan; J Michael Dean; Carol Nicholson
Journal:  Pediatrics       Date:  2010-04-19       Impact factor: 7.124

9.  Development and validation of a rapid liquid chromatography/tandem mass spectrometry method to quantitate gabapentin and buprenorphine in human serum.

Authors:  Sarah J Phillips; Alison Oliveto; Michael J Mancino; Howard P Hendrickson
Journal:  Rapid Commun Mass Spectrom       Date:  2021-07-31       Impact factor: 2.586

10.  Pregabalin for opioid-refractory pain in a patient with ankylosing spondylitis.

Authors:  Konstantinos A Kontoangelos; Anastasios V Kouzoupis; Panagiotis P Ferentinos; Ioannis D Xynos; Nikolaos V Sipsas; George N Papadimitriou
Journal:  Case Rep Psychiatry       Date:  2013-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.